Zelira Therapeutics Ltd has released a press release.
Appendix 4D & FY19 Interim Financial Report
Filed with ASX ·
6ix hasn’t read this filing yet.
Zelira Therapeutics Ltd. on 6ix
Earlier from Zelira Therapeutics
- December 2018 Quarterly Report and Board Transition
- ZLD to Invest in Development of Oral Spray Formulations
- Opioid reduction clinical trial with St Vincents Hospital
- September 2018 Quarterly Report
- Zelda Focuses Clinical Trial Activity
Later from Zelira Therapeutics
- Aus Patent For Novel Prognostic Marker for Breast Cancer
- Zelda Partners with Ilera HealthCare
- March 2019 Quarterly Report
- Zelda Granted Approval for Opioid Reduction Trial
- Response to ASX Price and Volume Query
Follow Zelira Therapeutics into a list and get an email when it puts out news.
Follow Zelira Therapeutics